oxazolidin-2-one has been researched along with Obesity in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Jia, M; Li, M; Li, Y; Pan, T; Sun, Y; Xiao, L; Xiao, Y; Zhou, L | 1 |
| Bateman, T; Blaustein, RO; Chen, Y; Hubert, J; Johns, DG; Rosa, R; Wang, SP; Xu, S | 1 |
| Fiedler-Kelly, J; Flanagan, S; Minassian, SL; Passarell, JA; Prokocimer, P | 1 |
| Antonelli, M; Bello, G; Cutuli, SL; De Pascale, G; Fortuna, S; Montini, L; Navarra, P; Pennisi, MA; Spanu, T; Tumbarello, M; Vallecoccia, M | 1 |
| Burton, A; Chavez-Eng, C; Gheyas, F; Gutstein, D; Hartmann, G; Jackson, T; Johns, D; Kumar, S; Lederman, H; Lutz, R; Mitra, K; Shen, X | 1 |
| Al-Huniti, N; Archer, L; Bergman, AJ; Chavez-Eng, C; Chen, J; Cote, J; Dykstra, K; Garg, A; Gottesdiener, K; Hilliard, D; Jin, B; Krishna, R; Laethem, T; Lasseter, KC; Lutz, R; Panebianco, D; Snyder, K; Van Bortel, L; Van Dyck, K; Van Hoydonck, P; Wagner, JA | 1 |
| Medico, CJ; Walsh, P | 1 |
| Hiraki, Y; Kamimura, H; Karube, Y; Kobayashi, T; Matsumoto, K; Mizoguchi, A; Morita, K; Sadoh, S; Sakamoto, S; Tsuji, Y; Yukawa, E | 1 |
| Antonelli, M; De Pascale, G; Fortuna, S; Navarra, P | 1 |
| Citron, DM; Goldstein, EJ; Havlichek, DH; Kak, V; Peloquin, CA; Schooley, SL; Stein, GE; Tyrrell, KL | 1 |
| Mersfelder, TL; Smith, CL | 1 |
1 review(s) available for oxazolidin-2-one and Obesity
| Article | Year |
|---|---|
Pharmacotherapy in the critically ill obese patient.
Topics: Aminoglycosides; Antithrombins; Arginine; Body Mass Index; Carbapenems; Cephalosporins; Drug Dosage Calculations; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Hypnotics and Sedatives; Lipopeptides; Obesity; Oxazolidinones; Penicillins; Pipecolic Acids; Protein C; Quinolones; Recombinant Proteins; Safety; Sulfonamides; Vancomycin | 2010 |
4 trial(s) available for oxazolidin-2-one and Obesity
| Article | Year |
|---|---|
Pharmacokinetics of Tedizolid in Obese and Nonobese Subjects.
Topics: Anti-Bacterial Agents; Humans; Obesity; Oxazolidinones; Tetrazoles | 2017 |
Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration.
Topics: Acetamides; Aged; Anti-Bacterial Agents; Critical Illness; Drug Monitoring; Female; Humans; Infusions, Intravenous; Linezolid; Male; Microbial Sensitivity Tests; Middle Aged; Obesity; Organ Dysfunction Scores; Oxazolidinones; Pneumonia, Ventilator-Associated; Prospective Studies; Risk Assessment; Rome | 2015 |
Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Cholesterol Ester Transfer Proteins; Cross-Over Studies; Double-Blind Method; Dyslipidemias; Fasting; Female; Humans; Male; Middle Aged; Obesity; Oxazolidinones; Sex Factors; Treatment Outcome; Young Adult | 2009 |
Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis.
Topics: Acetamides; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Area Under Curve; Cellulitis; Drug Resistance, Multiple, Bacterial; Female; Half-Life; Humans; Linezolid; Male; Microbial Sensitivity Tests; Middle Aged; Obesity; Oxazolidinones; Serum Bactericidal Test; Skin Diseases, Bacterial; Soft Tissue Infections | 2005 |
6 other study(ies) available for oxazolidin-2-one and Obesity
| Article | Year |
|---|---|
Epigoitrin alleviates lipid and glucose metabolic disorders induced by a high-fat diet.
Topics: Animals; Diet, High-Fat; Glucose Metabolism Disorders; Insulin Resistance; Lipid Metabolism; Lipids; Mice; Mice, Inbred C57BL; Obesity; Oxazolidinones | 2022 |
Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case.
Topics: Adipose Tissue, White; Animals; Biomarkers; Caloric Restriction; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Diet, High-Fat; Disease Models, Animal; Humans; Hypolipidemic Agents; Lipid Metabolism; Male; Mice; Obesity; Oxazolidinones; Tissue Distribution; Weight Loss | 2019 |
Disposition into Adipose Tissue Determines Accumulation and Elimination Kinetics of the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Mice.
Topics: Adipose Tissue; Animals; Cholesterol Ester Transfer Proteins; Diet; Kinetics; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; Oxazolidinones | 2016 |
Evaluation of the pharmacokinetics of linezolid in an obese Japanese patient.
Topics: Acetamides; Adult; Anti-Bacterial Agents; Humans; Japan; Linezolid; Lung Diseases; Male; Methicillin-Resistant Staphylococcus aureus; Obesity; Oxazolidinones; Staphylococcal Infections | 2012 |
Linezolid use in ventilator-associated pneumonia: look at the body weight of your patient!
Topics: Acetamides; Anti-Infective Agents; Area Under Curve; Body Weight; Humans; Linezolid; Methicillin-Resistant Staphylococcus aureus; Obesity; Oxazolidinones; Pneumonia, Ventilator-Associated; Staphylococcal Infections | 2012 |
Linezolid pharmacokinetics in an obese patient.
Topics: Acetamides; Adult; Anti-Infective Agents; Cellulitis; Half-Life; Humans; Linezolid; Male; Metabolic Clearance Rate; Obesity; Oxazolidinones | 2005 |